AbbVie announces extension of review for supplemental NDA of upadacitinib to treat psoriatic arthritis
AbbVie announced that the FDA has extended the review period for the supplemental New Drug Application (sNDA) for upadacitinib in the treatment of adult patients with active psoriatic […]